Evidence map›Paper›PMID 33639975›Full record

ArticleOrphanet journal of rare diseases2021

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population.

Enrique Rodríguez-Rubio, Helena Gil-Peña, Sara Chocron, Leire Madariaga, Francisco de la Cerda-Ojeda, Marta Fernández-Fernández, Carmen de Lucas-Collantes, Marta Gil, María Isabel Luis-Yanes, Inés Vergara and 12 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Mineral Metabolism in Children: Interrelation between Vitamin D and FGF23.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 19 institutions in 1 country.

Enrique Rodríguez-RubioPediatric Research, Medicine Department, University of Oviedo, Oviedo, Spain. erodrr00@gmail.com.ORCID http://orcid.org/0000-0002-3233-2283
Helena Gil-PeñaAGC Pediatría, Hospital Universitario Central de Asturias, Oviedo, Spain.
Sara ChocronServicio de Nefrología Pediátrica, Hospital Vall D'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
Leire MadariagaServicio Nefrología Pediátrica, IIS Biocruces-Bizkaia, Universidad del País Vasco UPV/EHU, Hospital Universitario Cruces, Barakaldo, Spain.
Francisco de la Cerda-OjedaUnidad de Nefrología Pediátrica, Hospital Virgen del Rocío, Sevilla, Spain.
Marta Fernández-FernándezServicio Pediatría, Complejo Asistencial Universitario de León, León, Spain.
Carmen de Lucas-CollantesServicio Nefrología, Hospital Niño Jesús, Madrid, Spain.
Marta GilServicio Pediatría, Hospital Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
María Isabel Luis-YanesServicio Pediatría, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
Inés VergaraServicio Pediatría, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain.
Juan David González-RodríguezUnidad de Nefrología, Hospital General Universitario Santa Lucia, Cartagena, Spain.
Susana FerrandoServicio de Pediatría, Hospital Clínico Universitario de Valencia, Valencia, Spain.
Montserrat Antón-GameroUnidad Nefrología Pediátrica, Hospital Universitario Reina Sofia, Córdoba, Spain.
Marta Carrasco Hidalgo-BarqueroUnidad de Nefrología Pediátrica, Hospital Universitario de Badajoz, Badajoz, Spain.
Angustias Fernández-EscribanoServicioNefrología Infantil, Hospital Infantil Gregorio Marañón, Madrid, Spain.
Mº Ángeles Fernández-MasedaUnidad de Nefrología Pediátrica, Hospital Virgen de la Salud, Toledo, Spain.
Laura EspinosaServicio Nefrología infantile, Hospital Universitario Infantil La Paz, Madrid, Spain.
Aniana OlietServicio Nefrología, Hospital Severo Ochoa, Leganés, Spain.
Antonio VicenteServicio Pediatría, Hospital Vega Baja, Orihuela, Spain.
Gema AricetaServicio de Nefrología Pediátrica, Hospital Vall D'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
Fernando SantosPediatric Research, Medicine Department, University of Oviedo, Oviedo, Spain.
RenalTubeGroup
Universidad de Oviedo · ESUniversitat Autònoma de Barcelona · ESCentro de Implantología Cirugía Oral y Maxilofacial · ESComplejo Asistencial Universitario de Palencia · ESComplejo Hospitalario Universitario de Santiago · ESComplexo Hospitalario Universitario A Coruña · ESHospital Clínico Universitario de Valencia · ESHospital Infantil Universitario Niño Jesús · ESHospital Materno-Infantil · ESHospital Universitario Central de Asturias · ESHospital Universitario La Paz · ESHospital Universitario Nuestra Señora de Candelaria · ESHospital Universitario Reina Sofía · ESHospital Universitario Severo Ochoa · ESHospital Universitario Virgen del Rocío · ESHospital Vega Baja · ESHospital Virgen de la Salud · ESSanta Lucía University General Hospital · ESUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundX-linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss-of-function mutations in PHEX gene leading tohypophosphatemia and high renal loss of phosphate. Rickets and growth retardation are the major manifestations of XLH in children, but there is a broad phenotypic variability. Few publications have reported large series of patients. Current data on the clinical spectrum of the disease, the correlation with the underlying gene mutations, and the long-term outcome of patients on conventional treatment are needed, particularly because of the recent availability of new specific medications to treat XLH.

resultsThe RenalTube database was used to retrospectively analyze 48 Spanish patients (15 men) from 39 different families, ranging from 3 months to 8 years and 2 months of age at the time of diagnosis (median age of 2.0 years), and with XLH confirmed by genetic analysis. Bone deformities, radiological signs of active rickets and growth retardation were the most common findings at diagnosis. Mean (± SEM) height was - 1.89 ± 0.19 SDS and 55% (22/40) of patients had height SDS below-2. All cases had hypophosphatemia, serum phosphate being - 2.81 ± 0.11 SDS. Clinical manifestations and severity of the disease were similar in both genders. No genotype-phenotype correlation was found. Conventional treatment did not attenuate growth retardation after a median follow up of 7.42 years (IQR = 11.26; n = 26 patients) and failed to normalize serum concentrations of phosphate. Eleven patients had mild hyperparathyroidism and 8 patients nephrocalcinosis.

conclusionsThis study shows that growth retardation and rickets were the most prevalent clinical manifestations at diagnosis in a large series of Spanish pediatric patients with XLH confirmed by mutations in the PHEX gene. Traditional treatment with phosphate and vitamin D supplements did not improve height or corrected hypophosphatemia and was associated with a risk of hyperparathyroidism and nephrocalcinosis. The severity of the disease was similar in males and females.

Indexed as

Familial Hypophosphatemic RicketsGenetic Diseases, X-LinkedHypophosphatemiaChildChild, PreschoolFemaleHumansMaleMutationPHEX Phosphate Regulating Neutral EndopeptidaseRetrospective StudiesPHEX Phosphate Regulating Neutral EndopeptidaseBone deformitiesGrowth retardationInherited hypophosphatemiaRicketsXLH

Identifiers

PMID33639975
PMCPMC7912818
OpenAlexW3108090184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.